Lirilumab - Bristol-Myers Squibb/Innate Pharma

Drug Profile

Lirilumab - Bristol-Myers Squibb/Innate Pharma

Alternative Names: Anti-KIR (1-7F9); Anti-KIR monoclonal antibody - Innate Pharma; BMS-986015; IPH-21; IPH-2101; IPH-2102; LIRI; NN 1975; ONO-4483

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Developer Bristol-Myers Squibb; Innate Pharma; National Cancer Institute (USA); Ono Pharmaceutical; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action KIR receptor antagonists; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Myelodysplastic syndromes
  • Phase I/II Solid tumours
  • Phase I Haematological malignancies; Multiple myeloma
  • Preclinical Lymphoma
  • Discontinued Acute myeloid leukaemia; Hepatitis C

Most Recent Events

  • 21 Nov 2017 Dana-Farber Cancer Institute and Bristol-Myers Squibb plan a phase II trial for Head and neck cancer (Recurrent, Combination therapy) in USA in December 2017 (NCT03341936)
  • 10 Oct 2017 Bristol-Myers Squibb completes a phase I trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA, Spain (IV) (NCT02252263)
  • 05 Jul 2017 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Metastatic disease, Combination therapy) in Japan (IV) (NCT03203876)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top